Rituximab biosimilar (Mabion)

利妥昔单抗生物类似药 (Mabion)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Mabion)

Drug Alias Name利妥昔单抗生物仿制药（Mabion）Rituximabum (Mabion)Rituximab (Mabion)MabionCD-20

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Large B-Cell, Diffuse

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusNDA/BLA

Highest Status in ChinaN/A

Originator CompaniesMabion Sa

China Registration ClassN/A

Develop Information

Active CompaniesMabion Sa

Inactive CompaniesN/A

Active IndicationsArthritis, RheumatoidLymphoma, Large B-Cell, Diffuse

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02